Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents

30 Jun 2017

Abstract excerpt

The prognosis of patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent (HMA) therapy is poor. Allogeneic hematopoietic cell transplantation (HCT) can be effective in curing patients who have failed therapy with HMA. However, published results have not addressed the outcomes with HCT in this setting. We identified 125 MDS patients who had been treated with HMA and underwent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Bone and Joint Diseases
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28600031
DOI: 10.1016/j.bbmt.2017.05.034

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating AgentsPMID 28600031Read ↗

Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.Semantic proximity Read ↗

Acute Myeloid Leukemia Patients With Myelodysplasia-Related Gene Mutations Benefit From Post-Transplant Hypomethylating Agent Maintenance.Semantic proximity Read ↗

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Semantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.Semantic proximity Read ↗

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Optimizing hypomethylating agents in myelodysplastic syndromesSemantic proximity Read ↗

Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.Semantic proximity Read ↗

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.Semantic proximity Read ↗

Therapy-related myelodysplasia and acute myeloid leukemia.Semantic proximity Read ↗

Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array TestingSemantic proximity Read ↗

Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.